Simple blood test could predict cancer in patients with Type 2 diabetes
Researchers have identified a biomarker that may be associated with an increased risk of obesity-related cancers in patients with Type 2 diabetes.
In a study presented at the European Association for the Study of Diabetes Annual Meeting 2024, the researchers examined baseline proinflammatory cytokines in 6,466 patients newly diagnosed with Type 2 diabetes.
After a follow-up of less than nine years, the researchers identified 327 cases of obesity-related cancers—including breast cancer, renal cell carcinoma, endometrial cancer, thyroid cancer, ovarian cancer and pancreatic cancer. The proinflammatory cytokine interleukin-6 was found to be linked to an increased risk of developing these cancers. Further, those who had the highest IL-6 levels were more likely to develop obesity-related cancers compared with those who had the lowest levels of IL-6.
The findings suggested that a simple blood test measuring IL-6 levels could potentially predict the risk of obesity-related cancers in patients with Type 2 diabetes.
Read more: EASD Annual Meeting 2024
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.